Aclaris Therapeutics Inc (ACRS) Receives $44.50 Consensus Price Target from Brokerages

Aclaris Therapeutics Inc (NASDAQ:ACRS) has been given a consensus recommendation of “Hold” by the seven analysts that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $44.50.

Several research firms have weighed in on ACRS. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Zacks Investment Research cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Finally, Guggenheim began coverage on Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 price objective on the stock.

Several hedge funds and other institutional investors have recently modified their holdings of ACRS. Franklin Resources Inc. increased its position in shares of Aclaris Therapeutics by 27.9% in the fourth quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock worth $64,037,000 after purchasing an additional 565,945 shares during the period. BlackRock Inc. increased its position in shares of Aclaris Therapeutics by 28.4% in the fourth quarter. BlackRock Inc. now owns 2,195,028 shares of the biotechnology company’s stock worth $54,129,000 after purchasing an additional 485,146 shares during the period. AXA bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth $6,455,000. FMR LLC increased its position in shares of Aclaris Therapeutics by 14.6% in the second quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock worth $51,425,000 after purchasing an additional 242,269 shares during the period. Finally, Driehaus Capital Management LLC increased its position in shares of Aclaris Therapeutics by 73.8% in the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock worth $12,908,000 after purchasing an additional 222,254 shares during the period. Institutional investors own 92.47% of the company’s stock.

Aclaris Therapeutics (ACRS) traded down $0.09 during mid-day trading on Tuesday, reaching $20.13. The company’s stock had a trading volume of 227,974 shares, compared to its average volume of 401,778. The company has a market cap of $620.71, a PE ratio of -9.32 and a beta of 1.26. Aclaris Therapeutics has a 1 year low of $18.46 and a 1 year high of $33.25.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://ledgergazette.com/2018/02/25/aclaris-therapeutics-inc-acrs-receives-44-50-consensus-price-target-from-brokerages.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply